

Monique B Nilsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862328/publications.pdf>

Version: 2024-02-01

29
papers

3,120
citations

361413

20
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

5463
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. <i>Molecular Cancer Research</i> , 2022, 20, 280-292. | 3.4 | 4 |
| 2 | Pozotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. <i>Cancer Cell</i> , 2022, 40, 754-767.e6. | 16.8 | 34 |
| 3 | Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215. | 1.1 | 149 |
| 4 | Altered Regulation of HIF-1 α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 439-451. | 1.1 | 34 |
| 5 | Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600. | 1.1 | 62 |
| 6 | Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2 α -Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839. | 1.1 | 34 |
| 7 | Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064. | 1.1 | 6 |
| 8 | ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. <i>Cancer Cell</i> , 2021, 39, 1178-1180. | 16.8 | 6 |
| 9 | Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737. | 27.8 | 185 |
| 10 | Inhibition of nonsense-mediated decay rescues p53 β isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. <i>Journal of Biological Chemistry</i> , 2021, 297, 101163. | 3.4 | 18 |
| 11 | Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324. | 1.5 | 17 |
| 12 | β -Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 27-36. | 4.1 | 35 |
| 13 | Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 33-40. | 2.0 | 12 |
| 14 | A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, . | 12.4 | 101 |
| 15 | Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623. | 1.1 | 43 |
| 16 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Pozotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. <i>Cancer Cell</i> , 2019, 36, 444-457.e7. | 16.8 | 145 |
| 17 | Mechanisms and clinical activity of an EGFR and HER2 exon 20 α -selective kinase inhibitor in non α -small cell lung cancer. <i>Nature Medicine</i> , 2018, 24, 638-646. | 30.7 | 351 |
| 18 | Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 246-257. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018, 24, 6195-6203. | 7.0 | 292 |
| 20 | Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284. | 1.8 | 12 |
| 21 | Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. <i>Science Translational Medicine</i> , 2017, 9, . | 12.4 | 96 |
| 22 | KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. <i>Clinical Cancer Research</i> , 2016, 22, 1940-1950. | 7.0 | 15 |
| 23 | Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0152584. | 2.5 | 65 |
| 24 | Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. <i>Oncotarget</i> , 2016, 7, 47998-48010. | 1.8 | 21 |
| 25 | Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy. <i>Cancer Research</i> , 2014, 74, 2731-2741. | 0.9 | 41 |
| 26 | An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290. | 7.0 | 848 |
| 27 | Stress Hormones Regulate Interleukin-6 Expression by Human Ovarian Carcinoma Cells through a Src-dependent Mechanism. <i>Journal of Biological Chemistry</i> , 2007, 282, 29919-29926. | 3.4 | 134 |
| 28 | Vascular endothelial growth factor (VEGF) pathway. <i>Journal of Thoracic Oncology</i> , 2006, 1, 768-70. | 1.1 | 22 |
| 29 | Interleukin-6, Secreted by Human Ovarian Carcinoma Cells, Is a Potent Proangiogenic Cytokine. <i>Cancer Research</i> , 2005, 65, 10794-10800. | 0.9 | 299 |